Cirrhosis and Complication: Treatment and Prognosis
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".
Deadline for manuscript submissions: closed (20 May 2023) | Viewed by 8660
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cirrhosis represents the end stage of chronic liver disease because of different causes, including viral hepatitis, autoimmune and genetic illnesses, alcohol abuse and metabolic disorders. The term cirrhosis includes clinical conditions with different grades of severity depending on onset of clinical complications, including gastrointestinal bleeding, hepatic encephalopathy (HE) and ascites. In addition, cirrhosis itself is largely the most important risk factor for the development of hepatocellular carcinoma (HCC).
Generally, when the complications linked to the portal hypertension appear, the liver damage from cirrhosis cannot be reversed, However, specific treatments can stop or delay further progression and reduce complications.
This Special Issue will be a collection of manuscripts providing an overview of the current research of treatment and prognosis in cirrhosis and complications.
The aim of this Special Issue is to provide a complete overview of the treatment and complications in the cirrhosis progression, finding any possible predictor of clinical outcome including specific treatment, lifestyle changes, involves molecular mechanisms, new drugs or surgery, and bacterial infections in cirrhosis. We welcome the submission of original papers and reviews regarding cirrhosis.
Prof. Dr. Irene Cacciola
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liver cirrhosis
- liver decompensation
- hepatic encephalopathy (HE)
- hepatocellular carcinoma (HCC)
- liver surgery
- bacterial infections in cirrhotic patients
- MAFLD
- hepatitis B and C viral infection
- DAA treatment
- nucleos(t)ide analog therapy
- predictors of cirrhosis progression
- new drugs in liver cirrhosis